Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

William Massey

Allergy & Immunology Birmingham, AL Medical Doctor

NPI 1316960271 CMS profile 150598

100 Pilot Medical Dr, Suite 100, Birmingham, AL 35235

Open in the dashboard

General payments

$3,054

169 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, William Massey of Birmingham, AL is reported in the CMS Open Payments database as having received $3,054 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $129 6
2021 General $728 34
2020 General $1,051 57
2019 General $1,146 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Massey
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to William Massey were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year William Massey Allergy & Immunology median Middle half National median
2019 $1,146 $594 $163–$1,512 $163
2020 $1,051 $426 $106–$1,233 $114
2021 $728 $638 $157–$1,708 $132
2022 $129 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $904 40 payments
  2. GlaxoSmithKline, LLC. $530 38 payments
  3. Genzyme Corporation $305 15 payments
  4. CSL Behring $285 13 payments
  5. OptiNose US, Inc. $225 15 payments
  6. Genentech USA, Inc. $188 15 payments
  7. Regeneron Healthcare Solutions, Inc. $117 6 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $103 5 payments
  9. Circassia Pharmaceuticals Inc $52 3 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $51 2 payments
  11. Other $294 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,054 169 payments
Products named General payments · program years 2019–2022
  1. FASENRA Respiratory $633 30 payments
  2. NUCALA Respiratory $275 22 payments
  3. Xhance $225 15 payments
  4. SPIRIVA RESPIMAT $205 10 payments
  5. Haegarda $201 9 payments
  6. Xolair $188 15 payments
  7. DUPIXENT Immunology $174 8 payments
  8. FASENRA Respiratory $172 4 payments
  9. DUPIXENT Immunology $156 8 payments
  10. NUCALA Immunology $130 8 payments
  11. Other $902 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record